(Q36909343)

17 August 2017

1 reference

title

Direct thrombin inhibition with bivalirudin as an antithrombotic strategy in general and interventional cardiology. (English)

1 reference

17 August 2017

3

Christoph Bode

1 reference

17 August 2017

Karlheinz Peter

4

0 references

author name string

Ingo Ahrens

series ordinal

1

1 reference

PubMed ID

17696810

17 August 2017

Belinda K Smith

series ordinal

2

1 reference

PubMed ID

17696810

17 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

Expert Opinion on Drug Metabolism & Toxicology

17 August 2017

1 reference

17 August 2017

3

1 reference

17 August 2017

4

1 reference

17 August 2017

609-620

1 reference

Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial

17 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

Use of GPIIb/IIIa inhibitors in cardiovascular medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

Cloning and expression of a cDNA coding for the anticoagulant hirudin from the bloodsucking leech, Hirudo medicinalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

Clinical pharmacology of bivalirudin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

Pharmacology and clinical use of bivalirudin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

Thrombin-directed inhibitors: pharmacology and clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

Predictions and associations of fatigue syndromes and mood disorders that occur after infectious mononucleosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

Bivalirudin for patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

A second look at bivalirudin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

Impact of diabetes mellitus on outcome of patients undergoing carotid artery stenting: insights from a single center registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

Adverse impact of bleeding on prognosis in patients with acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

Evolving management of ST-segment elevation myocardial infarction: update on recent data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: An analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.609

21 January 2018

Identifiers

DOI

10.1517/17425255.3.4.609

1 reference

17 August 2017

1 reference

PubMed ID

17696810